Edelweiss Capital Upgrades Sun Pharmaceutical Industries Ltd. (SUNP:IN) to Buy
- Wall Street extends rally as value stocks bounce
- China Tells Local Authorities to Prepare For a 'Possible Storm' and Prevent Unrest as Evergrande Crisis Unravels - WSJ
- Salesforce (CRM) Raises FY22 Revenue Guidance; Initiates FY23 Revenue
- Oil prices rise, hit 2-month highs on supply worries
- IDFA Seen as a 'Real Headwind' for Facebook (FB) but Analysts Remain Positive
Edelweiss Capital analyst Kunal Randeria upgraded Sun Pharmaceutical Industries Ltd. (SUNP:IN) from Hold to Buy with a price target of INR950.00 (from INR675.00).
You May Also Be Interested In
- Kone OYJ (KNEBV:FH) (KNYJY) PT Lowered to EUR74 at Berenberg
- Leucrotta Exploration Inc. (LXE:CN) (LCRTF) PT Raised to Cdn$1 at Stifel Canada
- CVS Group Plc. (CVSG:LN) (CVSGF) PT Raised to GBP29 at Berenberg
Create E-mail Alert Related CategoriesAnalyst PT Change, Intl Ratings, Upgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!